ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 315 for:    Recruiting, Not yet recruiting, Available Studies | kidney transplantation

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02158052
Recruitment Status : Recruiting
First Posted : June 6, 2014
Last Update Posted : March 16, 2018
Sponsor:
Information provided by (Responsible Party):
Thomas Spitzer, Massachusetts General Hospital

Brief Summary:
This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA) matched related donor combined bone marrow and kidney transplantation using a low dose total body irradiation based preparative regimen.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Amyloidosis Drug: Tacrolimus Drug: Anti-thymocyte globulin Procedure: Kidney transplant Drug: Bone marrow transplant from a related donor Radiation: Total body irradiation 400 centigray (200 cGy X 2) Not Applicable

Detailed Description:
The induction of transplantation tolerance involves the specific elimination of the immune response to the transplant but not to other antigens. In the realm of kidney transplantation, tolerance means that the recipient is unable to detect the donor transplant kidney as foreign, and therefore the recipient is unable to reject the kidney. Donor bone marrow engraftment leads to kidney graft tolerance in animal models. Renal failure is a major complication of multiple myeloma and AL amyloidosis for which the only known cure is allogeneic bone marrow transplantation. Standard bone marrow transplantation is associated with prohibitive toxicities in patients with end stage renal disease, and is generally not considered an option for those patients. Patients with multiple myeloma and AL amyloidosis are excluded from conventional renal transplantation protocols because of their underlying malignancy. A less toxic bone marrow transplantation protocol, utilizing low dose total body irradiation and anti-thymocyte globulin, combined with renal transplantation, could provide an opportunity for cure of the myeloma or amyloidosis and correction of end stage renal disease. In addition, successful marrow engraftment may be expected to lead to a state of tolerance. Successful implementation of tolerance would be a major benefit to transplant recipients. The significance of developing tolerance is that the patient could be spared the disabling complications of indefinite immunosuppression, which include infections, cataracts, osteoporosis, diabetes, atherosclerosis, hypertension, and malignancy.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combined HLA-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma or Other Hematologic Disorders With End Stage Renal Disease
Study Start Date : February 2015
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2021


Arm Intervention/treatment
Experimental: Transplantation
Single arm combined bone marrow and kidney transplantation
Drug: Tacrolimus
Tacrolimus starting on Day -1

Drug: Anti-thymocyte globulin
20 mg/kg IV on Days -3, -1, +1, +3

Procedure: Kidney transplant
On Day 0 the renal transplant is performed according to standard surgical techniques.

Drug: Bone marrow transplant from a related donor
Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.

Radiation: Total body irradiation 400 centigray (200 cGy X 2)
On transplant day -1




Primary Outcome Measures :
  1. The primary endpoint is the renal allograft rejection rate at 6 months post-transplant. [ Time Frame: Participants will be followed on an intention-to-treat basis, and data from all enrolled participants will be collected, irrespective of outcome, for the scheduled minimum follow-up period of 3 years. ]

    BUN and creatinine will be measured daily while hospitalized, then weekly up to 100 days, then at month 6, and years 1, 1.5, 2, 3.

    Renal biopsies will be performed as clinically indicated for suspected rejection



Secondary Outcome Measures :
  1. Assess anti-tumor response rates in patients with hematologic malignancies [ Time Frame: Participants will be followed on an intention-to-treat basis, and data from all enrolled participants will be collected, irrespective of outcome, for the scheduled minimum follow-up period of 3 years. ]
    • Bone marrow biopsy and aspirate for patients with hematologic malignancy and prior bone marrow involvement (pre-transplant, Day 100, 6 months, year 1, year 2).
    • Quantification of serum and urine M protein and serum free light chain analyses for patients with myeloma (Days 35, 70, 100, month 6, year 1, year 1.5, year 2, year 3).
    • Quantitative immunoglobulin analysis (Days 7, 14, 21, 28, 42, 56, 70, 84, 100, month 6, year 1, year 1.5, year 2, year 3).
    • Additional disease staging procedures and studies for other hematologic malignancies as clinically indicated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Participant Inclusion Criteria

  • Participants with end-stage renal failure due to or in association with multiple myeloma or systemic AL amyloidosis which hematopoietic cell transplantation is appropriate and a ≥ 50% five-year survival probability with transplantation is expected. This includes, but is not limited to:
  • Multiple myeloma (MM), ISS stage II or III in complete or very good partial remission
  • AL amyloidosis without significant cardiac disease
  • Males or females 18 - 65 years of age.
  • Participants must have an HLA-matched or one of six HLA A, B, or DR antigen-mismatched related donor, with high resolution molecular class I and II allele typing.
  • Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 2 years following the transplant.
  • Participants should be on dialysis or have a CrCl <20 ml/min.
  • Patients should not have evidence of renal recovery of their renal failure over a 90 day period of therapy for their underlying malignancy or other blood disorder.
  • Patients with a history of other malignancies excluding basal cell carcinoma of the skin and carcinoma in situ of the cervix with a disease-free survival interval of >2 years. Patients with the following malignancies must demonstrate a 5 year disease-free survival:

    • Breast cancer with positive nodes
    • Malignant melanoma (other than in situ)
    • Colorectal cancer (other than Dukes Stage A or B1)
  • Patients with multiple myeloma must have received previous treatment with a bortezomib-based regimen.

Patients with AL amyloidosis must have received previous treatment with a bortezomib-based regimen and/or autologous stem cell transplantation

  • Patients with a history of malignant melanoma must be reviewed by an independent oncologist prior to enrollment.
  • Recipient ability to understand and provide informed consent.

Participant Exclusion Criteria

  • Evidence of active infection as defined by: a) clinical syndrome consistent with viral or bacterial infection (e.g., influenza, URI, UTI) or b) fever with a clinical site of infection identified, or c) microbiologically documented infection, including, but not limited to, bacteremia or septicemia.
  • Participation in other investigational drug use at the time of enrollment.
  • Contraindication to therapy with any one of the proposed agents (e.g., history of allergy to horse serum in ATG).
  • Serologic positivity to HIV or HCV.
  • Women of childbearing age in whom adequate contraception cannot be maintained.
  • AST/ALT > 3 x normal or bilirubin > 1.5 x normal (unless due to Gilbert's syndrome).
  • Pregnancy or uncontrolled serious medical illness not related to underlying myeloma.
  • Cardiac ejection fraction < 40% by echocardiogram.
  • FEV1 < 50% predicted or corrected DLCO < 50% predicted.
  • ABO blood group incompatibility in the host-vs-graft direction.

    • Diagnosis of myelodysplastic syndrome

Donor Inclusion Criteria

  • HLA-matched or one of six HLA A, B, or DR antigen-mismatched related male or female donor 18-65 years of age.
  • ECOG performance status 0 or 1.
  • Excellent health per conventional pre-donor history (medical and psychosocial evaluation).
  • Acceptable laboratory parameters (hematology in normal or near-normal range; liver function < 2 times the upper limit of normal and normal creatinine).
  • Compatible ABO blood group.
  • Negative donor lymphocyte crossmatch.
  • No positive testing for viral infection (HbsAg, HIV, HCV, HTLV-1).
  • Cardiac/Pulmonary evaluation within normal limits (CXR, EKG).
  • Donor ability to understand and provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02158052


Contacts
Contact: Thomas R Spitzer, MD 617-724-1124 tspitzer@partners.org

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Thomas R Spitzer, MD    617-724-1124    tspitzer@partners.org   
Sponsors and Collaborators
Massachusetts General Hospital

Responsible Party: Thomas Spitzer, Director, Bone Marrow Transplant Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT02158052     History of Changes
Other Study ID Numbers: KdBMT-2
First Posted: June 6, 2014    Key Record Dates
Last Update Posted: March 16, 2018
Last Verified: March 2018

Keywords provided by Thomas Spitzer, Massachusetts General Hospital:
HLA matched
bone marrow transplantation
kidney transplantation

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Kidney Diseases
Kidney Failure, Chronic
Amyloidosis
Hematologic Diseases
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Proteostasis Deficiencies
Metabolic Diseases
Tacrolimus
Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action